real-world safety analysis of deferiprone in patients with mds
Published 1 year ago • 271 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:47
real-world data on the safety of emicizumab in patients with hemophilia a
-
1:39
real-world efficacy & safety of teclistamab in patients with bcma-pretreated r/r multiple myeloma
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
7:54
patient/caregiver stories - living with mds
-
![why design history file (dhf) is important? [alexandros savvidis]](https://i.ytimg.com/vi/X9GediGNWk4/mqdefault.jpg)
35:59
why design history file (dhf) is important? [alexandros savvidis]
-
7:51
real-world data and its real-world use
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
1:30
the prognostic value of patient-reported outcomes in mds
-
3:38
safety and activity of ceralasertib in the treatment of mds
-
1:16
state of the art: mds
-
2:10
drd versus vrd in patients with mm: a real-world retrospective analysis
-
2:07
emerging targeted treatments for mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:34
perspectives on the management of low and high-risk mds
-
3:12
worldwide access to efficacious agents in mds needs improvement
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
7:09
the role of real-world evidence in the evaluation of new drugs
-
2:43
novel therapies in the future of mds treatment
-
1:13
horizon scan of mds treatments